Tampa Convention Center.
(2) Wieting S., et al. HPV-013 Month 18 Extension Abstract. Presented at
the European Society of Paediatric Infectious Diseases (ESPID) annual
meeting on 2-4 May 2007
(3) GSK Data on File
(4) Schuind A. HPV-007 Final Analysis. To be presented at: SGO's Annual
Meeting on Women's Cancer. March 10, 2008
(5) Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for
squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix
compared to women with normal cytology in The Netherlands. Br J
(6) Liu S, Semenciw R, et al. Cervical cancer: the increasing incidence
of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ
2001; 164: 1151-1152.
(7) Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a
bivalent L1 virus-like particle vaccine against human papillomavirus
types 16 and 18: follow-up from aluminium control trial. The Lancet
2006; 367: 1247-1255.
(8) Gall, S., et al. Sustained Efficacy up to 5.5 years in women
vaccinated with an AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine.
Presented at AACR Medical Meeting. April 17, 2007
(9) Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic
cervical human papillomavirus infection. Infect Dis Clin North Am,
(10) Munoz N, Bosch FX, de Sanjose S,et al. Epidemiologic classification
of human papillomavirus types associated with cervical cancer. N Engl
J Med 2003; 348: 518-527
(11) Munoz N, Bosch FX, Castellsague X et al. Against which human
papillomavirus types shall we vaccinate and screen? The international
perspective. Int. J. Cancer 2004; 111; 278-285
Copyright©2008 PR Newswire.
All rights reserved